Schrödinger, Inc. provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates through two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. has strategic collaborations with Thermo Fisher Scientific to extend the use of cryo-EM in connection within silico compound screening to accelerate drug discovery; Bristol Myers Squibb Company to discover, develop, and commercialize therapeutics in multiple disease areas; NVIDIA designed to harness DGX SuperPODs; Zai Lab Limited to discover, develop, and commercialize a program in oncology targeting DNA damage response; and The University of Texas MD Anderson Cancer center to develop WEE1 program. The company was incorporated in 1990 and is headquartered in New York, New York.
IPO Year: 2020
Exchange: NASDAQ
Website: schrodinger.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/2/2024 | $29.00 | Outperform | Leerink Partners |
12/5/2023 | $38.00 | Overweight | KeyBanc Capital Markets |
5/5/2023 | $60.00 | Overweight | Piper Sandler |
12/19/2022 | $23.00 | Neutral | Goldman |
3/1/2022 | $55.00 | Buy | Citigroup |
11/19/2021 | $82.00 → $49.00 | Overweight → Equal-Weight | Morgan Stanley |
11/19/2021 | $87.00 | Overweight | Piper Sandler |
11/11/2021 | $80.00 → $52.00 | Buy → Neutral | B of A Securities |
10/13/2021 | $91.00 | Buy | Berenberg |
9/1/2021 | $82.00 | Equal-Weight → Overweight | Morgan Stanley |
SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)
SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)
SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)
SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)
SC 13G - Schrodinger, Inc. (0001490978) (Subject)
SC 13G - Schrodinger, Inc. (0001490978) (Subject)
SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)
SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)
SC 13G - Schrodinger, Inc. (0001490978) (Subject)
SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)
8-K - Schrodinger, Inc. (0001490978) (Filer)
S-8 - Schrodinger, Inc. (0001490978) (Filer)
10-Q - Schrodinger, Inc. (0001490978) (Filer)
8-K - Schrodinger, Inc. (0001490978) (Filer)
8-K - Schrodinger, Inc. (0001490978) (Filer)
DEFA14A - Schrodinger, Inc. (0001490978) (Filer)
10-Q - Schrodinger, Inc. (0001490978) (Filer)
8-K - Schrodinger, Inc. (0001490978) (Filer)
ARS - Schrodinger, Inc. (0001490978) (Filer)
DEFA14A - Schrodinger, Inc. (0001490978) (Filer)
4 - Schrodinger, Inc. (0001490978) (Issuer)
4 - Schrodinger, Inc. (0001490978) (Issuer)
4 - Schrodinger, Inc. (0001490978) (Issuer)
4 - Schrodinger, Inc. (0001490978) (Issuer)
4 - Schrodinger, Inc. (0001490978) (Issuer)
4 - Schrodinger, Inc. (0001490978) (Issuer)
4 - Schrodinger, Inc. (0001490978) (Issuer)
4 - Schrodinger, Inc. (0001490978) (Issuer)
4 - Schrodinger, Inc. (0001490978) (Issuer)
4 - Schrodinger, Inc. (0001490978) (Issuer)
Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer. Dr. Porges brings to Schrödinger more than 30 years of experience in executive, advisory and investment roles within the biopharmaceutical industry. As Schrödinger's CFO, he will lead all aspects of the company's financial operations and investor relations and corporate affairs activities. He will also oversee business development and strategic planning for the company's proprietary pharmaceuticals and biopharmaceutical collaborations. This press release features multim
Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Arun Oberoi to its Board of Directors, effective May 17, 2022. Mr. Oberoi will serve as a member of the Audit Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005040/en/Arun Oberoi was appointed to Schrödinger's Board of Directors in May 2022. He will serve on the company's Audit Committee. (Photo: Business Wire) "We are very pleased to welcome Arun to our Board," said Ramy Farid, Ph.D., president and chief executive officer of Schrödinger. "Aru
During the last three months, 4 analysts shared their evaluations of Schrodinger (NASDAQ:SDGR), revealing diverse outlooks from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 0 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $30.25, a high estimate of $37.00, and a low estimate of $25.00. This current average has decreased by 12.75% from t
Keybanc analyst Scott Schoenhaus maintains Schrodinger (NASDAQ:SDGR) with a Overweight and lowers the price target from $30 to $25.
Leerink Partners analyst Mani Foroohar initiates coverage on Schrodinger (NASDAQ:SDGR) with a Outperform rating and announces Price Target of $29.
Citigroup analyst David Lebowitz maintains Schrodinger (NASDAQ:SDGR) with a Buy and lowers the price target from $39 to $37.
Craig-Hallum analyst Matt Hewitt maintains Schrodinger (NASDAQ:SDGR) with a Buy and lowers the price target from $35 to $30.
U.S. stock futures were higher this morning, with the Dow futures gaining over 150 points on Thursday. Shares of Etsy, Inc. (NASDAQ:ETSY) fell sharply in today's pre-market trading after the company reported worse-than-expected first-quarter financial results. Etsy reported first-quarter revenue of $645.954 million, which missed the consensus estimate of $646.33 million, according to Benzinga Pro. The company reported quarterly earnings of 48 cents per share, which missed estimates of 49 cents per share. Etsy shares tumbled 13.2% to $60.45 in pre-market trading. Here are some big stocks recording losses in today's pre-market trading session. Fastly, Inc. (NYSE:FSLY) shares di
2024 Software revenue growth is expected to range from 6% to 13%. Drug discovery revenue is expected to range from $30 million to $35 million. Software gross margin is expected to be similar to software gross margin for the full year 2023.
Gainers Pulmonx (NASDAQ:LUNG) shares rose 29.5% to $10.0 during Wednesday's after-market session. The market value of their outstanding shares is at $388.1 million. The company's, Q1 earnings came out today. Butterfly Network (NYSE:BFLY) shares moved upwards by 18.15% to $0.93. The company's market cap stands at $193.5 million. As per the press release, Q1 earnings came out today. Compass Therapeutics (NASDAQ:CMPX) stock rose 11.46% to $1.75. The market value of their outstanding shares is at $240.7 million. Sharps Technology (NASDAQ:STSS) shares increased by 9.2% to $0.27. The market value of their outstanding shares is at $4.2 million. Blueprint Medicines (NASDAQ:BPMC) shares moved up
Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on August 14, 2024, the company granted restricted stock units (RSUs) with respect to 7,500 shares of the company's common stock to 13 newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a com
Schrödinger (NASDAQ:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference. The live presentation will take place on Wednesday, September 4, 2024, at 3:20 p.m. ET. The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based computational platform that enables discover
Second Quarter Total Revenue of $47.3 Million, Software Revenue of $35.4 Million Launches Major Initiative to Expand Application of Computational Tools for Predictive Toxicology Initial Clinical Data Expected for SGR-1505 in 1H25, SGR-2921 and SGR-3515 Data in 2H25 Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced financial results for the second quarter of 2024. "We are very pleased with our results for the second quarter. We delivered 21% software revenue growth, and we see many opportunities for customers to increase their scale of adoption of our technology. Our recently
Initiative initially funded by $10 million grant from the Bill & Melinda Gates Foundation Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that it is embarking on an initiative to expand its computational platform to predict toxicology risk early in drug discovery. The goal of the initiative is to develop a computational solution designed to improve the properties of novel drug development candidates and reduce the risk of development failure associated with binding to off-target proteins, which can be associated with serious side effects. This initiative is an expansion of Schröd
Schrödinger (NASDAQ:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its second quarter 2024 financial results on Wednesday, July 31, 2024, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based computational platform that enables discovery of high-quality, novel molecule
Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on July 12, 2024, the company granted restricted stock units (RSUs) with respect to 9,990 shares of the company's common stock to eight newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a co
Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on June 11, 2024, the company granted (i) a non-statutory stock option to purchase 2,400 shares of the company's common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 9,420 shares of the company's common stock to seven newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material indu
SHANGHAI, June 4, 2024 /PRNewswire/ -- The 2024 Forbes Midas List, a distinguished industry list of the world's best venture capital investors, has been unveiled. Nisa Leung, Managing Partner at Qiming Venture Partners, has become a Forbes Midas Lister for the sixth consecutive year, ranking 40th this year. The Forbes Midas List celebrates honorees' extraordinary investment insights and accomplishments. Nisa and her team have shown a strong commitment to identifying startups that enhance the healthcare system while addressing global unmet medical needs. Over the past decade, Nisa and her team have overseen over 220 healthcare companies, including Gan & Lee Pharmaceuticals (SHSE:603087), Sin
Schrödinger (NASDAQ:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference. The live presentation will take place on Wednesday, June 5, 2024, at 2:30 p.m. ET. The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based computational platform that enables discovery of high-quality, novel mole
Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on May 16, 2024, the company granted restricted stock units (RSUs) with respect to 4,090 shares of the company's common stock to three newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a com
Leerink Partners initiated coverage of Schrodinger with a rating of Outperform and set a new price target of $29.00
KeyBanc Capital Markets initiated coverage of Schrodinger with a rating of Overweight and set a new price target of $38.00
Piper Sandler resumed coverage of Schrodinger with a rating of Overweight and set a new price target of $60.00
Goldman initiated coverage of Schrodinger with a rating of Neutral and set a new price target of $23.00
Citigroup initiated coverage of Schrodinger with a rating of Buy and set a new price target of $55.00
Morgan Stanley downgraded Schrodinger from Overweight to Equal-Weight and set a new price target of $49.00 from $82.00 previously
Piper Sandler initiated coverage of Schrodinger with a rating of Overweight and set a new price target of $87.00
B of A Securities downgraded Schrodinger from Buy to Neutral and set a new price target of $52.00 from $80.00 previously
Berenberg initiated coverage of Schrodinger with a rating of Buy and set a new price target of $91.00
Morgan Stanley upgraded Schrodinger from Equal-Weight to Overweight and set a new price target of $82.00
Second Quarter Total Revenue of $47.3 Million, Software Revenue of $35.4 Million Launches Major Initiative to Expand Application of Computational Tools for Predictive Toxicology Initial Clinical Data Expected for SGR-1505 in 1H25, SGR-2921 and SGR-3515 Data in 2H25 Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced financial results for the second quarter of 2024. "We are very pleased with our results for the second quarter. We delivered 21% software revenue growth, and we see many opportunities for customers to increase their scale of adoption of our technology. Our recently
Schrödinger (NASDAQ:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its second quarter 2024 financial results on Wednesday, July 31, 2024, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based computational platform that enables discovery of high-quality, novel molecule
First Quarter Total Revenue of $36.6 Million, Software Revenue of $33.4 Million Announces FDA Clearance of Investigational New Drug Application for SGR-3515, a Novel Wee1/Myt1 Inhibitor SGR-1505 and SGR-2921 on Track for Initial Phase 1 Data Readouts in Late 2024 or 2025 Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced financial results for the first quarter of 2024. "Over the past year, we have witnessed unprecedented interest in computational drug discovery, and we are excited by the growing appreciation for using computation to drive pharmaceutical innovation. We are exci
Schrödinger (NASDAQ:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its first quarter 2024 financial results on Wednesday, May 1, 2024, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based computational platform that enables discovery of high-quality, novel molecules f
Achieved Fourth Quarter Software Revenue of $68.7 Million, a 44% Increase Over Fourth Quarter 2022 Delivered 20% Annual Total Revenue Growth, with Total Revenue of $216.7 Million Expects Software Revenue Growth of 6% to 13% in 2024 Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced financial results for the fourth quarter and full-year ended December 31, 2023, and provided its financial outlook for 2024. "I am very pleased with the progress we made in 2023, delivering 20 percent total revenue growth and reporting our largest quarter for software revenue in our history. We also
Schrödinger (NASDAQ:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its fourth quarter and full-year 2023 financial results on Wednesday, February 28, 2024, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based computational platform that enables discovery of high-quali
Announces Expanded Multi-Year Software Agreement with Lilly Continued Focus in 2024 on Advancing Science Underlying Platform, Driving Software Adoption and Progressing Proprietary Pipeline Schrödinger, Inc. (NASDAQ:SDGR), Schrödinger (NASDAQ:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today provided an update on its progress across the business and announced its development and operational goals for 2024. Today Schrödinger announced an expanded, three-year, software agreement with Eli Lilly and Company. The three-year agreement builds on the collaboration established in 2022. The agreement provides Lilly with lar
Delivers Third Quarter Total Revenue of $42.6 Million; Maintains Full-Year 2023 Revenue Guidance Continued Progress for SGR-1505, Healthy Volunteer Data Expected in Fourth Quarter of 2023 Phase 1 Study Initiated for SGR-2921; Discloses PRMT5-MTA Discovery Program BMS Returns Two Programs From Collaboration Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced financial results for the quarter ended on September 30, 2023. "Schrodinger had an excellent third quarter marked by strong revenue growth and significant pipeline progress. More of our software customers are increasing th
Schrödinger (NASDAQ:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its third quarter 2023 financial results on Wednesday, November 1, 2023, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed under "News & Events" in the investors section of Schrödinger's website, https://ir.schrodinger.com/news-and-events/event-calendar. The archived webcast will be available on Schrödinger's website for approximately 90 days following the event. About Schrödinger Schrödinger is transforming the way therapeutics and materials are discov
Announces IND Clearance for CDC7 Inhibitor SGR-2921, Continued Progress for MALT1 Inhibitor SGR-1505 Delivers Second Quarter Total Revenue of $35.2 Million Raises 2023 Software Revenue Guidance and Reduces Drug Discovery Guidance Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced financial results for the quarter ended on June 30, 2023. "This year, we've witnessed unprecedented interest in computational drug discovery and, as leaders in this field, we are excited by the growing recognition that computational approaches can transform pharmaceutical innovation," said Ramy Farid,